2011, Radiation medicine rounds, ISBN 1936287366, Volume 2, issue 2., xi, 338
Book
1989, 2nd ed. --, ISBN 9780443085970, x̃ix, 1132 p., [6] p. of col. plates
Book
2006, Foundations in diagnostic pathology, ISBN 9780443069604, xvi, 611
Book
2003, 4th ed., ISBN 9780721694801, xviii, 850
Book
1990, ISBN 0865773491, x, 243
Book
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1856 - 1867
Patients with platinum-refractory head and neck cancer had significantly longer survival with nivolumab treatment than with standard, single-agent therapy....
LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SCORES | PHASE-3 TRIAL | OPEN-LABEL | QUALITY-OF-LIFE | DOCETAXEL | CHEMOTHERAPY | EGFR | Carcinoma, Squamous Cell - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Head and Neck Neoplasms - metabolism | B7-H1 Antigen - metabolism | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents - adverse effects | Nivolumab | Survival Analysis | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Complications and side effects | Squamous cell carcinoma | Care and treatment | Chemotherapy | Usage | Cancer | Head | PD-1 protein | Body weight | Cancer therapies | Patients | Quality of life | Metastases | Platinum | Monoclonal antibodies | Death | Neck | Head & neck cancer | Methotrexate | Apoptosis
LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SCORES | PHASE-3 TRIAL | OPEN-LABEL | QUALITY-OF-LIFE | DOCETAXEL | CHEMOTHERAPY | EGFR | Carcinoma, Squamous Cell - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Head and Neck Neoplasms - metabolism | B7-H1 Antigen - metabolism | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents - adverse effects | Nivolumab | Survival Analysis | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Complications and side effects | Squamous cell carcinoma | Care and treatment | Chemotherapy | Usage | Cancer | Head | PD-1 protein | Body weight | Cancer therapies | Patients | Quality of life | Metastases | Platinum | Monoclonal antibodies | Death | Neck | Head & neck cancer | Methotrexate | Apoptosis
Journal Article
1974, ISBN 0683004751, x, 388
Book
Book
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 583 - 594
Summary Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC) progressing after first-line platinum regimens...
Hematology, Oncology and Palliative Medicine | CHEMOTHERAPY PLUS CETUXIMAB | SOLID TUMORS | EFFICACY | BIOMARKER | ONCOLOGY | HUMAN-PAPILLOMAVIRUS | RETROSPECTIVE ANALYSIS | P16(INK4A) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Male | Treatment Outcome | Platinum - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Neoplasm Metastasis | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Afatinib | Aged, 80 and over | Adult | Female | Methotrexate - administration & dosage | Quinazolines - administration & dosage | Aged | Medical colleges | Care and treatment | Relapse | Carcinoma | Product development | Metastasis | Methotrexate | Cancer | Diseases
Hematology, Oncology and Palliative Medicine | CHEMOTHERAPY PLUS CETUXIMAB | SOLID TUMORS | EFFICACY | BIOMARKER | ONCOLOGY | HUMAN-PAPILLOMAVIRUS | RETROSPECTIVE ANALYSIS | P16(INK4A) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Male | Treatment Outcome | Platinum - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Neoplasm Metastasis | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Afatinib | Aged, 80 and over | Adult | Female | Methotrexate - administration & dosage | Quinazolines - administration & dosage | Aged | Medical colleges | Care and treatment | Relapse | Carcinoma | Product development | Metastasis | Methotrexate | Cancer | Diseases
Journal Article
2000, ISBN 9781900151993, 208
Head and neck ultrasound is a standard radiological examination performed at most hospitals. It is an important topic and all specialist registrars in...
Head | Ultrasonic imaging | Neck
Head | Ultrasonic imaging | Neck
Book
11.
Diagnosis [and] treatment of tumors of the head and neck
: not including the central nervous system
Book
1996, 3rd ed., ISBN 0721655505, xix, 964
Book
2008, ISBN 1597560804, xii, 184 p., [12] p. of plates
Book
1981, ISBN 0443080458, 905
Book
Book
Book
1987, ISBN 9783136856017, 332 p. in various pagings
Book
Cancer, ISSN 0008-543X, 09/2012, Volume 118, Issue 18, pp. 4444 - 4451
BACKGROUND: Adenoid cystic carcinoma (ACC) of the head and neck (ACCHN) is a rare tumor of minor salivary, parotid, and submandibular glands. The biologic...
adenoid | adenoid cystic | salivary gland tumors | head and neck cancer | adenoid cystic carcinoma | CANCER SURVIVAL | RISK | FACTORS INFLUENCING SURVIVAL | TUMORS | CHEMOTHERAPY | RADIATION-THERAPY | ORIGIN | ONCOLOGY | SALIVARY-GLAND CARCINOMA
adenoid | adenoid cystic | salivary gland tumors | head and neck cancer | adenoid cystic carcinoma | CANCER SURVIVAL | RISK | FACTORS INFLUENCING SURVIVAL | TUMORS | CHEMOTHERAPY | RADIATION-THERAPY | ORIGIN | ONCOLOGY | SALIVARY-GLAND CARCINOMA
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.